WO2001032207A1 - Procede permettant d'appliquer une immunotherapie active/passive - Google Patents

Procede permettant d'appliquer une immunotherapie active/passive Download PDF

Info

Publication number
WO2001032207A1
WO2001032207A1 PCT/US2000/001112 US0001112W WO0132207A1 WO 2001032207 A1 WO2001032207 A1 WO 2001032207A1 US 0001112 W US0001112 W US 0001112W WO 0132207 A1 WO0132207 A1 WO 0132207A1
Authority
WO
WIPO (PCT)
Prior art keywords
immunogen
hapten
ligand
target antigen
patient
Prior art date
Application number
PCT/US2000/001112
Other languages
English (en)
Inventor
Fred Manley Cowan
Original Assignee
United States Army Medical Research And Materiel Command
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by United States Army Medical Research And Materiel Command filed Critical United States Army Medical Research And Materiel Command
Priority to AU27291/00A priority Critical patent/AU2729100A/en
Publication of WO2001032207A1 publication Critical patent/WO2001032207A1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/385Haptens or antigens, bound to carriers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6012Haptens, e.g. di- or trinitrophenyl (DNP, TNP)

Definitions

  • the present invention relates to methods for priming human and other mammalian immune systems to thereby confer upon them the ability to react immediately to a wide variety of antigenic substances previously unseen by the immune system.
  • the present Active/Passive Immunotherapy (API) invention is designed to combine the advantages of active standing and passive instant immunization.
  • API is accomplished by first giving an active immunization with a hapten and/or immunogen (H/I).
  • H/I or antigen determinant of said H/I is further conjugated to an antigen binding ligand that can be an antibody, antibody fragment, peptide or chemical capable of binding to a pathological "target" antigen(s).
  • an antigen binding ligand can be an antibody, antibody fragment, peptide or chemical capable of binding to a pathological "target" antigen(s).
  • active standing "sentinel" immunity to said H/I has developed, the subject is administered a passive immunization that comprises the ligand-H/I wherein the ligand grants instant passive binding to the target antigen.
  • the ligand-H/I conjugate acts as a "sandwich” molecule to usurp the active standing immunity for the H/I to passive instant immunity to
  • the mammalian immune system comprises humoral antibody and cellular immunity to antigenic determinants, "target” antigens or "pathological” antigens.
  • Pathological antigens include infectious agents such as bacteria, viruses and mycological agents, toxins, chemicals, cancer cells and in the case of autoimmunity, an organism's own tissues or portions thereof.
  • the immune system functions to identify, attack and neutralize pathological antigens. Another function of the immune system is to maintain a mammal's tolerance to self-antigens. Both of these functions can be augmented by active or passive immunization. Active
  • an antigen is by way of vaccination with the antigen or by exposure through infection by a microbe or the breach of epidermal layers caused by injury or infection.
  • the immune system After a period of time following exposure to the antigen, typically a few days or weeks, the immune system has processed the antigen to produce antigen-specific cells, and/or antibodies to the antigen.
  • the antigen-specific cells and antibodies to the antigen are the "memory" of the organism's immune system regarding that specific antigen.
  • the antigen-specific memory cells comprise the organism's "cellular" response to the antigen.
  • the antigen-specific antibodies comprise the "humoral" response of the organism. Some antigens produce only a cellular response while others produce only a humoral response. Still other antigens produce both a humoral and a cellular response. Together, the cellular and humoral response components to a specific antigen comprise the "active" or "standing” response of the organism to the antigen.
  • Mammals and other organisms also have "passive" immunity to many antigens. Passive immunity to an antigen can be either innate or provided. The innate passive immunity to many antigens possessed by many organisms is at least partly a result of selective pressures of co-evolution of the organism with many microbes. Typically, mammals have innate passive immunity to hundreds of thousands or millions of antigens. Passive immunity can also be provided, however, by the injection or other administration of antigen-specific cells or antibodies.
  • the immune response can select for cellular or humoral immunity for the best mode for neutralization of the target antigen.
  • humoral immunity is generally best for neutralizing toxins and bacteria, and cellular immunity for viral and cancer antigens.
  • the ability of the natural immune response to select primarily either a humoral or cellular, or appropriate combination of humoral and cellular immunity to a pathological antigen is a critical function of the immune response.
  • the lack of effectiveness of many immunotherapies is a direct result of their failure to achieve appropriate activation of cellular and humoral immune responses.
  • Haptens and immunogens can comprise small synthetic molecules that are not cross reactive with naturally occurring antigen determinants.
  • Haptens can elicit only humoral immune response and are antigenic only when conjugated to a carrier molecule, e.g., peptide or chemical, that is an immunogen.
  • Immunogens elicit both humoral and cellular immunity, but can be selective for cellular immunity.
  • Bifunctional antigens can have both hapten and immunogen determinants.
  • a hapten, immunogen, or bifunctional hapten-immunogen can be selective for either humoral and/or cellular immunity to achieve an optimal balance of humoral and cellular immunity.
  • Vaccines have not been realized for many pathological antigens and it is a critical limitation of both vaccination and passive immunotherapy that often only non-selective or partial humoral or cellular immune responses are achieved.
  • API could provide a generic defense against the myriad of pathological antigens to include infectious agents, autoimmune and cancer antigens.
  • API overcomes a number of problems that are associated with other immunotherapies such as vaccination, anti-sera, monoclonal antibodies, superantigen-ligand, anti-Fc receptor- ligand, and Staphylococcus aureus protein A-ligand. These include: (1) An intact antibody in anti-sera or monoclonal antibody preparations developed in one species, e.g., horse, mouse, can when administered to another species elicit immunity to the antibody, limiting the clinical use of the antibody. The small size and selective antigenic stimulation by ligand-H/I conjugate should greatly reduce or even eliminate this obstacle.
  • the reagents for immunization of a subject to H/I and production of ligand conjugated to H/I can be achieved by known and inexpensive synthesis processes. This allows ligand-H/I to be administered at doses that are compatible with natural concentrations of humoral antibody and levels of cellular immunity.
  • the H/I conjugated to the ligand can be a single monovalent antigenic determinant so as not to aggregate either antibody of cellular receptors until the target antigen is engaged.
  • Ligands can be designed to achieve the desired valence, specificity and affinity for a given antigen determinant(s), and a specific ligand need not be limited to a peptide or a hapten.
  • immunogens may include other types of molecules such as chemicals. This allows chemicals that are used to image or bind to pathological antigens to be used as ligands.
  • the method may also help antigen processing, thus establishing immunity to pathogenetic antigenic determinants that normally only weakly simulate immunity.
  • the method can neutralize any antigen that can be bound to a ligand by selectively stimulating a partial or the full immune repertoire to include all antibody classes and cellular immune responses elicited by the H/I.
  • API can be administered as prophylaxis or therapy as a medical countermeasure to an identified pathological antigen or as a broad spectrum antigen binding ligand that could be used to neutralize an entire class of pathogen such as gram negative bacteria.
  • withdrawing administration of the ligand H/I conjugate can terminate the API immune response and any toxic side effects.
  • U.S. Patent 5,189,014 issued on Feb. 23, 1993 to Cowan and entitled "A Method for Treating Cellular Fc Receptor Mediated Immune Disorders” discloses a method of treating immune complex diseases and associated pathological immune regulation using Fc receptors (FcR) or FcR-like bacterial proteins, such as Staphylococcus aureus protein A (SPA).
  • FcR Fc receptors
  • SPA Staphylococcus aureus protein A
  • the method of anti- T cell ligand-hapten of Lussow et al. selected for only humoral immunity against T cells and they were able to achieve only a ⁇ 50% reduction of circulating T cells (p. 262, top col. 2). Although they attribute this to non-specific binding of anti- T cell ligand, the lack of the cellular response to T cells in their system may have contributed to the failure to more substantially clear T cells from circulation. In any case, the presence of cellular immunity to the circulating T cells may well have overcome this limitation of T cell destruction.
  • the prior art and the Lussow et al. publication make no mention of the utility of chemical antigen binding ligands to target pathological antigens or immunogens to activate cellular immunity.
  • the present API invention includes the use of chemical ligands and immunogens providing both advantages over concepts beyond the scope of the prior art and the Lussow et al. article.
  • chemical ligands allows chemicals that are routinely used to image and more "generically" bind pathological antigens, such as vital stains, to be used as antigen binding ligands. Furthermore, this improvement will stimulate routine testing of known chemicals and synthesis of new compounds for use as antigen binding ligands.
  • immunogens which, like haptens, can be small chemical molecules such as L- tyrosine-p-azobenzenearsonate (ABA-Tyr), but unlike haptens can select for cellular immunity, gives a distinct advantage over the use of haptens to generate purely humoral immunity.
  • ABA-Tyr L- tyrosine-p-azobenzenearsonate
  • the present invention Active/Passive Immunotherapy, combines active standing immunization to a hapten or immunogen and passive instant immunization with an antigen binding ligand for a pathological target antigen, conjugated to the H/I.
  • Prior immunization to the H/I grants active standing immunity whereas the ligand grants instant passive binding to the target antigen.
  • the ligand-H/I conjugate acts as a "sandwich" molecule to usurp the active standing immunity for the H/I to passive instant immunity to the pathological target antigen.
  • the ligand-DNP conjugate, the ligand-ABA conjugate or the ligand- H/I conjugate functions to provide binding sites of the appropriate types so that presensitized immune cells can bind with the target antigen complex.
  • a particular advantage of the present invention is that the full immune repertoire of humoral and cellular immunity can be instantly and selectively mobilized and focused toward the target pathological antigen.
  • the present invention can achieve either a selective or a full immune repertoire that balances the optimal combination of humoral and cellular immunity to any antigen that can be bound by a ligand.
  • the present invention provides an immunotherapeutic system that emulates portions of the natural immune response yet offers the previously unknown advantages of a primed generic immune defense against a myriad of pathological antigens such as infectious agents, toxins, autoimmune and cancer cell antigens.
  • a method for conferring humoral immunization to a target antigen comprising: A) administering a sufficient amount of a hapten-carrier conjugate to a patient for a sufficient length of time to confer upon the patient active standing immunization to the hapten including the proliferation of antibodies to the hapten, and B) administering to the patient a sufficient amount of a hapten-ligand conjugate wherein the ligand of the conjugate has at least one binding site to the target antigen and the hapten of the conjugate is available for binding with the antibodies such that the target antigen becomes complexed with the hapten-ligand conjugate and with the antibodies to the extent that the target antigen undergoes neutralization by the immune cells of the patient.
  • the ligand is an antibody, an antibody fragment, a peptide or a non-peptide chemical capable of binding to the target antigen.
  • the ligand is not an antibody or antibody fragment but is capable of binding to the target antigen.
  • the ligand can be a chemical used to image or bind to pathological antigens.
  • the neutralization typically occurs by processes typical to the mammalian immune system. These processes include antibody mediated complement attack, cellular cytotoxicity and T cell destruction, that is, the phagocytosing of the immune complexes by the patient's immune cells.
  • the target antigen in the present invention can similarly be a toxin or a non-peptide chemical, or a portion of a bacteria, virus, mycological agent, cancer cell or the patient's own tissues.
  • a method is provided of conferring immunization to a target antigen comprising: A) administering a sufficient amount of an immunogen or a hapten-immunogen conjugate to a patient for a sufficient length of time to confer upon the patient, i) active standing immunity to the immunogen or hapten including the proliferation of antibodies to the hapten, and ii) active standing immunity to the immunogen including the proliferation of activated immune cells having binding sites for the immunogen.
  • a hapten-ligand conjugate wherein the ligand of the conjugate has at least one binding site to the target antigen and the hapten or immunogen of the conjugate is available for binding with the binding sites on the activated immune cells such that the target antigen immediately elicits both humoral and cellular responses from the patient to the extent that the target antigen undergoes neutralization by the immune cells of the patient.
  • the immunogen is selected so that administering the hapten-immunogen conjugate also confers upon the patient active standing immunity to the immunogen in the form of both proliferation of antibodies to the hapten and cellular immunity to the immunogen.
  • the ligand is an antibody, an antibody fragment, a peptide or a non-peptide chemical capable of binding to the target antigen.
  • the ligand is not an antibody or antibody fragment but is capable of binding to the target antigen.
  • the ligand can be a chemical used to image or bind to pathological antigens.
  • the present methods can be used against many different target antigens, for example, where the target antigen is a toxin or a non-peptide chemical, or a portion of a bacteria, virus, mycological agent, cancer cell or the patient's own tissues.
  • the present methods can be used with many immunogens including, among others, where the immunogen is a toxin or a non-peptide chemical, or a portion of a bacteria, virus, mycological agent, cancer cell or the patient's own tissues.
  • Immunogens of the present invention can be small synthetic molecules that are not cross-reactive with naturally occurring antigen determinants.
  • an immunogen can be selected such that it elicits both humoral and cellular responses to the target antigen or such that the immunogen elicits only a cellular response to the target antigen.
  • the ligand is an antibody, an antibody fragment, a peptide or a non-peptide chemical capable of binding to the target antigen.
  • the ligand is not an antibody or antibody fragment but is capable of binding to the target antigen.
  • the ligand can be a chemical used to image or bind to pathological antigens.
  • the neutralization typically occurs by the phagocytosing of the immune complexes by the patient's immune cells.
  • Figure 1 schematically shows a hapten or immunogen ⁇ "H/I"), antigen binding ligand ("Ligand”) and their combination to form a "ligand-H/I conjugate” moiety useful in the present methods.
  • Figure 2 schematically shows a Ligand-H/I conjugate according to the invention bound both to an anti-H/I Receptor on an immune system cell and to a target antigen.
  • the target antigen is shown also bound by an Anti-H/I Antibody specific to the target antigen.
  • Figure 3 schematically shows the molecular formula of an exemplary hapten, DNP, coupled to an exemplary immunogen, ABA-Tyr by means of a covalently bound spacer molecule.
  • Figure 4 schematically shows the hapten DNP coupled to a ligand and the immunogen ABA-Tyr coupled to a ligand.
  • Haptens are generally peptides or chemicals of small molecular weight (MW), e.g., about 100 to about 1000 daltons MW. Immunization with a hapten bound to an immunogenic protein or a non-peptide chemical immunogen carrier molecule produces a humoral (antibody) immune response. Immunogens can be large macromolecules, however, for use as reagents for practicing the methods of the present invention. Immunogens that are peptides or chemicals of small molecular weight are most suitable.
  • Immunogens can produce humoral immunity or be selective for cellular immunity alone.
  • Antigen binding ligands can be intact antibodies, Fab2 , Fab, Fv regions antibody fragments, peptides or, also like haptens and immunogens, may be chemicals that selectively bind pathological antigens.
  • the immunological art is replete with descriptions of a multitude of peptide and chemical molecules that are haptens, immunogens and antigen binding ligands. Methods for immunization with haptens or immunogens and conjugation of chemicals and peptides to form ligand-H/I conjugates are also well known in the field. Therefore, as one of skill in the art will recognize, the present invention allows for numerous combinations of specific haptens, immunogens and antigen binding ligands. Thus, the following description and examples are exemplary and not limiting.
  • Active/Passive Immunotherapy comprises combining active immunization to hapten or immunogen (H/I) and passive immunization with an antigen binding ligand- H/I conjugates to transfer active standing immunity from the H/I to a pathological target antigen.
  • Figure 1 shows schematically a hapten or immunogen ⁇ "H/I"), antigen binding ligand ("Ligand”) and their combination to form a "ligand-H/I conjugate" moiety useful in the present methods.
  • EXAMPLE 2 Active/Passive Immunotherapy (API) usurps antigen specific cellular and humoral immunity from H/I to pathological antigen.
  • Figure 2 shows schematically a ligand-H/I conjugate according to the invention bound both to an anti-H/I receptor on an immune system cell and to a target antigen.
  • the target antigen is shown also bound by an anti-H/I antibody specific to the target antigen.
  • Haptens such as dinitrophenyl (DNP) coupled to a carrier molecule can stimulate humoral antibody to DNP; whereas immunogens such as L-tyrosine-p-azobenzenearsonate (ABA-Ty) activate cellular immunity.
  • immunogens such as L-tyrosine-p-azobenzenearsonate (ABA-Ty) activate cellular immunity.
  • a bifunctional hapten - spacer - immunogen. such as dinitophenyl-6-aminocaproyl- L-tyrosine-p-azobenzenearsonate (DNP-ABA-Tyr), can induce antibodies specific for the DNP hapten determinant and cellular immunity to the ABA-Tyr immunogen determinant.
  • Figure 3 shows one species according to the present invention comprising three moieties.
  • An exemplary hapten, dinitrophenyl (DNP), and an exemplary immunogen, L- tyrosine-p-azobenzenearsonate (ABA-Tyr) are shown connected by a spacer molecule to form an exemplary bifunctional hapten-immunogen DNP-ABA-Tyr.
  • Immunization with the hapten-DNP-carrier causes a humoral anti-DNP antibody immune response, that is, the production of anti-DNP antibodies.
  • Immunization with the immunogen ABA causes an anti- ABA cellular immune response, that is, the production of immune cells having ABA receptors.
  • Immunization with the bifunctional hapten-immunogen DNP-ABA-Tyr causes both an anti-DNP humoral and anti-ABA cellular response.
  • the hapten DNP can be coupled to a ligand and the immunogen ABA-Tyr can be coupled to a ligand.
  • Active/Passive Immunotherapy can be induced in a subject that has been immunized to a bifunctional hapten-spacer-immunogen such as DNP-ABA-Tyr to achieve an optimal balance of humoral and/or cellular immunity to a target antigen.
  • a subject administered an antigen binding ligand conjugated to DNP would gain (humoral) antibody- mediated immunity.
  • a subject administered a ligand- ABA-Tyr conjugate would gain cellular immunity to the ligand's target antigen.
  • a subject administered both ligand-hapten and ligand-immunogen achieves both humoral and cellular immunity to the target antigen.
  • Figure 4 shows DNP and ABA conjugated to an antigen binding ligand.
  • DNP conjugate, ligand-ABA conjugate or ligand-H/I conjugate acts as a "sandwich" molecule to usurp the active standing immunity for the H/I to passive immunity to the pathological target antigen.
  • the ligand-DNP conjugate, ligand-ABA conjugate or ligand-H/I conjugate functions to provide binding sites of the appropriate types so that presensitized immune cells can bind with the target antigen complex.
  • a particular advantage of the present method is that the full immune repertoire of humoral and/or cellular immunity can be instantly and selectively mobilized and focused toward the target pathological antigen.
  • the ligand-DNP selects for humoral immunity; whereas, the ligand-ABA selects for cellular immunity.
  • ligand-H/I API By combining active immunization to H/I and passive immunization to ligand-H/I API can achieve either a selective humoral or cellular, or a full immune repertoire that balances the optimal humoral and/or cellular immunity to any particular antigen that can be bound by an antigen binding ligand.
  • the toxin ricin is used as a prototypic antigen (inactivated and bound to tanned sheep red blood cells [SRBC] by glutaraldehyde). Ricin and monoclonal antibody to ricin serve as a prototypic antigen binding ligand.
  • the anti-ricin antibodies are cleaved by the protease pepsin to Fab2 fragments and isolated for use as antigen binding ligand.
  • the anti-ricin ligand is conjugated to the chemical immunogen L-tyrosine-p-azobenzenearsonate (ABA-Tyr), that is a prototypic immunogen.
  • ABA-Tyr chemical immunogen L-tyrosine-p-azobenzenearsonate
  • a standard model for foot pad delayed hypersensitivity (DH) is used to test for cellular immunogen mediated API, in ABA sensitized mice.
  • the prototypic reagents i.e., antigen, antigen binding ligand and immunogen, are exemplary and not limiting.
  • a chemical antigen binding ligand could be substituted for the anti- ricin antibody.
  • the reagents listed below are incubated in vitro and washed to remove unbound reagents.
  • Reagents (1 ,2,3) are negative controls.
  • (4) is an API test sample and (5) is a positive control.
  • Reagents (1,2,3,4.5) are passively administered to the hind foot pad of mice sensitized to ABA and also sensitized to ricin in (5) positive control.
  • Twenty four hour post challenge animals are sacrificed and control (left) and test (right) foot pads harvested and weighed. The ratio of the weight of the test foot pad divided by the weight of the control foot pad is determined. Foot pad swelling that yields a ratio, e.g. >2, indicates a positive delayed hypersensitivity reaction.
  • the toxin ricin is used as a prototypic antigen (inactivated and bound to tanned sheep red blood cells [SRBC] by glutaraldehyde).
  • the anti-ricin antibodies are cleaved by the protease pepsin to Fab2 fragments and isolated, to be used as antigen binding ligand that is a prototype for a chemical ligand.
  • the anti-ricin ABA are then conjugated to the chemical hapten DNP (dinitrophenol).
  • Rabbit anti-DNP antisera is commercially available.
  • Standard C (complement) and ADCC (antibody dependent cellular cytoxicity) assays and the passive cutaneous Arthus reaction are used as prototypic models for testing humoral chemical ligand- API.
  • reagents listed below are incubated in vitro and washed to remove unbound reagents.
  • Reagents (1-5) are incubated with rabbit anti-DNP antibody in the presence of mouse sera, heat inactivated mouse sera (56° C, 30 min) or spleenic leukocytes to assay for complement and ADCC mediated lysis of SRBC (hemoglobin release).
  • the optimum M [C] (molar concentration) of intact anti-ricin (Fc+) for lysis of Ricin-SRBC in the C and ADCC assays serves as a guide for selection of M [C] of anti-ricin (Fab). If complement and ADCC mediated lysis of SRBC is by API. the lysis will be apparent in the (4) test sample and (5) positive control, and not in control samples (1 -3).
  • the optimum [C] of reagents in the in vitro experiments serves as a guide or starting point for determining the optimum [C] of reagents in vivo.
  • Reagents (1,2,3) negative controls and (4) API test sample are incubated with anti- DNP antibody, washed to remove soluble reagents and passively administered to mice subcutaneous (sc).
  • One hour post challenge animals are infused with Evans blue iv, and, at 2 hours, the animals are sacrificed and checked to determine if a cutaneous Arthus reaction is present, as measured by infusion of dye into the skin.
  • Four animals are tested in each group and each animal receives four sc test injections of different [C] (selected from results of in vitro studies) of reagents (1,2,3) as negative controls, and (5) as positive control.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne l'immunothérapie active/passive qui allie l'immunisation active faisant intervenir un haptène ou immunogène (H/I) à une immunisation passive faisant intervenir le même H/I conjugué à un ligand se fixant à un antigène. L'immunisation active assure une immunité permanente active tandis que le ligand se fixant à un antigène assure une liaison passive à l'antigène cible. Le conjugué ligand-H/I joue le rôle d'une molécule « sandwich » fournissant des sites de liaison à l'antigène cible et aux cellules immunitaires de manière à remplacer l'immunité active associée au H/I par l'immunité passive associée à l'antigène cible pathologique. L'invention présente des avantages découlant de l'utilisation des produits chimiques et des peptides comme ligands se fixant à un antigène, de la mobilisation instantanée et sélective d'un répertoire immunologique complet d'une immunité humorale et/ou cellulaire et du ciblage d'un antigène pathologique. Ainsi, l'immunothérapie active/passive peut offrir une défense générique à l'encontre d'une myriade d'antigènes pathologiques comprenant des microbes et d'autres agents infectieux, des toxines ainsi que des antigènes auto-immuns et cancéreux.
PCT/US2000/001112 1998-10-30 2000-01-19 Procede permettant d'appliquer une immunotherapie active/passive WO2001032207A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU27291/00A AU2729100A (en) 1999-10-29 2000-01-19 Methods for conferring active/passive immunotherapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14575298P 1998-10-30 1998-10-30
US42949199A 1999-10-29 1999-10-29
US09/429,491 1999-10-29

Publications (1)

Publication Number Publication Date
WO2001032207A1 true WO2001032207A1 (fr) 2001-05-10

Family

ID=26843262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/001112 WO2001032207A1 (fr) 1998-10-30 2000-01-19 Procede permettant d'appliquer une immunotherapie active/passive

Country Status (1)

Country Link
WO (1) WO2001032207A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7033594B2 (en) * 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
EP1729799A2 (fr) * 2004-01-09 2006-12-13 Kary B. Mullis Immunite programmable chimiquement
US7422746B2 (en) * 1999-12-22 2008-09-09 Altermune, Llc Chemically programmable immunity
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US8604184B2 (en) 2009-05-05 2013-12-10 The United States Of America As Represented By The Secretary Of The Air Force Chemically programmable immunity
US20150030535A1 (en) * 2010-10-08 2015-01-29 City Of Hope Meditopes and meditope-binding antibodies and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037690A2 (fr) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Conjugues cytomodulants d'elements de paires de liaison specifiques
WO1998008875A1 (fr) * 1996-08-28 1998-03-05 Viva Diagnostika Diagnostische Produkte Gmbh Nouvelles preparations combinees et leur utilisation en immunodiagnostic et en immunotherapie
WO1998022141A2 (fr) * 1996-11-19 1998-05-28 Sangstat Medical Corporation Effets renforces pour therapeutique associee a l'haptene

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997037690A2 (fr) * 1996-04-10 1997-10-16 Sangstat Medical Corporation Conjugues cytomodulants d'elements de paires de liaison specifiques
WO1998008875A1 (fr) * 1996-08-28 1998-03-05 Viva Diagnostika Diagnostische Produkte Gmbh Nouvelles preparations combinees et leur utilisation en immunodiagnostic et en immunotherapie
WO1998022141A2 (fr) * 1996-11-19 1998-05-28 Sangstat Medical Corporation Effets renforces pour therapeutique associee a l'haptene

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBASE [online] ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL; MANZKE O. ET AL: "CD3X anti-nitrophenyl bispecific diabodies: Universal immunotherapeutic tools for retargeting T cells to tumors.", XP002141435, retrieved from STN Database accession no. 1999266437 *
INTERNATIONAL JOURNAL OF CANCER, (1999) 84/5 (700-708). *
LEMLEY P V ET AL: "Mice are actively immunized after passive monoclonal antibody prophylaxis and ricin toxin challenge.", IMMUNOLOGY, (1992 JUL) 76 (3) 511-3., XP000915036 *
LUSSOW A R ET AL: "TARGETING OF ANTIHAPTEN ANTIBODIES TO ACTIVATED T CELLS VIA AN IL-2-HAPTEN CONJUGATE PROLONGS CARDIAC GRAFT SURVIVAL", TRANSPLANTATION,US,WILLIAMS AND WILKINS, BALTIMORE, MD, vol. 62, no. 12, 27 December 1996 (1996-12-27), pages 1703 - 1708, XP002050537, ISSN: 0041-1337 *
MOOLTEN F.L. ET AL: "Antibodies conjugated to potent cytotoxins as specific antitumor agents.", IMMUNOLOGICAL REVIEWS, (1982) VOL. 62/- (47-73). CODEN: IMRED2, XP000915030 *

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236321B2 (en) 1999-12-22 2012-08-07 Altermune Technologies, Llc Chemically programmable immunity
US8591910B2 (en) 1999-12-22 2013-11-26 Altermune Technologies Llc Chemically programmable immunity
US7422746B2 (en) * 1999-12-22 2008-09-09 Altermune, Llc Chemically programmable immunity
US8263082B2 (en) 1999-12-22 2012-09-11 Altermune Technologies Llc Chemically programmable immunity
US7645743B2 (en) * 1999-12-22 2010-01-12 Altermune, Llc Chemically programmable immunity
US7850975B2 (en) 1999-12-22 2010-12-14 Altermune Technologies, Llc Chemically programmable immunity
US7033594B2 (en) * 2000-03-31 2006-04-25 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
US8105608B2 (en) 2000-03-31 2012-01-31 Purdue Research Foundation Method of treatment using ligand-immunogen conjugates
AU2005213962B2 (en) * 2004-01-09 2009-11-05 Altermune, Llc Chemically programmable immunity
EP1729799A4 (fr) * 2004-01-09 2008-11-05 Kary B Mullis Immunite programmable chimiquement
AU2010200609B2 (en) * 2004-01-09 2013-05-16 Altermune, Llc Chemically programmable immunity
EP1729799A2 (fr) * 2004-01-09 2006-12-13 Kary B. Mullis Immunite programmable chimiquement
US8168164B2 (en) 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
US8604184B2 (en) 2009-05-05 2013-12-10 The United States Of America As Represented By The Secretary Of The Air Force Chemically programmable immunity
US20150030535A1 (en) * 2010-10-08 2015-01-29 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US9669108B2 (en) * 2010-10-08 2017-06-06 City Of Hope Meditopes and meditope-binding antibodies and uses thereof
US11246942B2 (en) 2010-10-08 2022-02-15 City Of Hope Meditopes and meditope-binding antibodies and uses thereof

Similar Documents

Publication Publication Date Title
AU667460B2 (en) Targeted immunostimulation with bispecific reagents
Green et al. The behavior of hapten-poly-L-lysine conjugates as complete antigens in genetic responder and as haptens in nonresponder guinea pigs
Uhr et al. Antibody formation: I. The suppression of antibody formation by passively administered antibody
US6113901A (en) Methods of stimulating or enhancing the immune system with anti-CD3 antibodies
Rosenberg et al. Ability of antigen-specific helper cells to effect a class-restricted increase in total Ig-secreting cells in spleens after immunization with the antigen.
US20010048922A1 (en) Targeted immunostimulation with bispecific reagents
Havas The effect of the carrier protein on the immune response and on the induction of tolerance in mice to the 2, 4-dinitrophenyl determinant
FI58501B (fi) Foerfarande foer framstaellning av ett antigenkomplex foer blockering av allergiska reaktioner
JPS6345228A (ja) 抗原の免疫原性の増強
JP2009227680A (ja) 腸球菌抗原およびワクチン
US4816253A (en) Novel mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
GB1599454A (en) Antigen-d-glutamic acid d-lysine copolymer conjugates for induction of immunological tolerance
JPH11509558A (ja) 免疫反応を惹起するための、多数エピトープ含有抗原の再構成法および組成物
US4567041A (en) Mutant strain of Listeria monocytogenes and its use in production of IgM antibodies and as an immunotherapeutic agent
JP2001501579A (ja) 抗体の産生、及び抗体を含む医療的使用
JPS60155133A (ja) アンチ−イデイオタイプのモノクロナル抗体を採用したアンチ−イデイオタイプワクチン
WO2001032207A1 (fr) Procede permettant d'appliquer une immunotherapie active/passive
Palladino et al. Immune response differences between two inbred chicken lines identical at the major histocompatibility complex
Petty et al. The effect of immunological adjuvants on the relative affinity of anti-protein antibodies.
Fairchild et al. Induction of mouse homocytotropic antibodies to timothy pollen antigens
McDowell et al. Reaction of staphylococcal protein A with rabbit immunoglobulins
US5358710A (en) Method for the suppression of an immune response
Azar Termination of Acquired Immunological Tolerance in Mice with Antigen Aggregates.
US5173293A (en) Anti-T-cell antibodies as adjuvants
Cruse et al. Mechanisms of Immunological Enhancement1, 2

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase